Endothelialization of Amplatzer PFO Occluder Device 12 Months After Implantation: First-in-Human Angioscopic...

Area of Science:

• Cardiovascular Medicine
• Medical Devices
• Interventional Cardiology

Background:

• Current guidelines recommend 6 months of antithrombotic and antibiotic prophylaxis post-atrial septal occluding device placement, based on "until endothelialization."
• In vivo human assessment of neo-endothelialization following device implantation is lacking.
• Previous autopsy and explant studies suggest incomplete endothelialization beyond 6 months, linked to complications like endocarditis and thrombosis.

Observation:

• A novel angioscopy technique was developed to visualize and assess device endothelialization.
• This method was utilized to evaluate the endothelialization of a 25 mm Amplatzer PFO occluder device in a patient 12 months post-implantation.
• This marks the first in vivo evaluation of PFO occluder device endothelialization in humans.

Findings:

• The study successfully demonstrated the feasibility of using angioscopy for in vivo assessment of device endothelialization.
• The evaluation of the PFO occluder device at 12 months provides crucial data on its endothelialization status.
• Findings highlight the need to re-evaluate the current 6-month prophylaxis guideline.

Implications:

• The developed angioscopy method offers a new tool for monitoring device healing and assessing endothelialization in real-time.
• This research may lead to revised clinical guidelines for post-procedural prophylaxis duration, potentially reducing complications.
• Understanding in vivo endothelialization is critical for optimizing patient outcomes and device performance in atrial septal defect closure.